Last $1.77 USD
Change Today +0.0305 / 1.75%
Volume 22.0K
CRMD On Other Exchanges
As of 8:04 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

cormedix inc (CRMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/14 - $3.20
52 Week Low
11/20/13 - $0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CORMEDIX INC (CRMD)

Related News

No related news articles were found.

cormedix inc (CRMD) Related Businessweek News

No Related Businessweek News Found

cormedix inc (CRMD) Details

CorMedix Inc., a development-stage pharmaceutical and medical device company, intends to in-license, develop, and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases. The company’s product candidates include CRMD003 (Neutrolin) and CRMD004, an antimicrobial/antifungal and anticoagulant combination in liquid and gel formulations used for the prevention of catheter-related blood stream infections and maintenance of catheter patency in hemodialysis patients. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Bridgewater, New Jersey.

2 Employees
Last Reported Date: 03/31/14
Founded in 2006

cormedix inc (CRMD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $223.5K
Vice Chairman, Chief Scientific Officer and C...
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2013.

cormedix inc (CRMD) Key Developments

CorMedix, Inc. to Report Q2, 2014 Results on Aug 14, 2014

CorMedix, Inc. announced that they will report Q2, 2014 results on Aug 14, 2014

U.S. Food and Drug Administration Accepts CorMedix , Inc.'s Pivotal Phase 3 Study Protocol

CorMedix Inc. announced that U.S. Food and Drug Administration (FDA) has agreed with the design of pivotal Phase III protocol for Neutrolin(R) in Hemodialysis patients, and the company plans to submit the IND for Neutrolin within the next 30 days. The FDA will then have 30 days to respond to the IND. The pivotal Phase 3 randomized controlled trial for Neutrolin is for use in hemodialysis patients with a central venous catheter. The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe. Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program.

CorMedix, Inc. Announces the Addition of Two Executives to the Management Team

CorMedix, Inc. announced the addition of two executives to the management team. Harry O'Grady joins the company as Chief Financial Officer and Dr. Antony Pfaffle transitions from Interim Chief Scientific Officer to a full time Chief Scientific Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRMD:US $1.77 USD +0.0305

CRMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRMD.
View Industry Companies

Industry Analysis


Industry Average

Valuation CRMD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORMEDIX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at